Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate

The Thomsen-Friedenreich (TF) antigen is a key target for the development of anticancer vaccines, and this ongoing challenge remains relevant due to the poor immunogenicity of the TF antigen. To overcome this challenge, we adopted a bivalent conjugate design which introduced both the TF antigen and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleski, Kristopher A., Trabbic, Kevin R., Shi, Mengchao, Bourgault, Jean-Paul, Andreana, Peter R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144725/
https://www.ncbi.nlm.nih.gov/pubmed/32183149
http://dx.doi.org/10.3390/molecules25061319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144725/
https://www.ncbi.nlm.nih.gov/pubmed/32183149
http://dx.doi.org/10.3390/molecules25061319

Ejemplares similares